Arthneeti
VO

Valiant Organics Ltd

Q3 FY25Chemicals & Petrochemicals

Valiant Organics Ltd Q3 FY25 Results & Presentation Highlights: Revenue, Margins & Order Book

Q3 FY25 investor presentation: what the company reported on revenue, margins and projects.

Price₹411
Market cap₹1.2K Cr
P/E23.7
Updated24 Sept 2026
Read4 min read

Based on Valiant Organics Ltd's Q3 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Q3-FY25 Consolidated Revenue from Operations: INR 1,869 Mn, up 32.2% YoY from INR 1,414 Mn (Page 12, 14). Q3-FY25 Consolidated Financials (Page 9 and 12): - EBITDA: INR 154 Mn, up from INR 38 Mn in Q3-FY24 (approx.

From Valiant Organics Ltd's Q3 FY25 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q3-FY25 Consolidated Revenue from Operations: INR 1,869 Mn, up 32.2% YoY from INR 1,414 Mn (Page 12, 14).
  • Q3-FY25 Standalone Revenue from Operations: INR 1,869 Mn, up 32.2% YoY from INR 1,414 Mn (Page 14).
  • Sales Volumes growth across key chemistries (Chlorination, Hydrogenation, Ammonolysis) shown with volumes increasing Q3-FY24 to Q3-FY25, e.g., Chlorination volumes rose from 366 MT to 879 MT (Page 11).
  • 9M-FY25 Consolidated Revenue from Operations: INR 5,149 Mn, slight increase of 2.9% YoY from INR 5,004 Mn (Page 15).

2 more points management made on revenue & sales performance

Profitability & Margins

See what Valiant Organics Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The investor presentation (pages reviewed) does not explicitly provide details on any capital expenditure (capex), capacity expansion, or new plant/project with amounts, status, or specific timelines. It mentions existing manufacturing facilities and capacities (page 6), including units specialized in chlorination, ammonolysis, hydrogenation, methoxylation, acetylation, and sulphonation, but no ongoing or planned expansions or new projects are described. The document focuses on financial performance, operations, and market information without detailing future capex or capacity expansion projects.

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

5x potential
1Shiv Texchem Ltd
Rev 1Mar 2
2Yasho Industries
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Valiant Organics Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation does not explicitly report any details regarding order book, order inflow, or pending orders. The document focuses on: - Financial performance data (revenue, EBITDA, PAT, margins) - Shareholding and capital market information - Operational highlights including production volumes and revenue break-up by key chemistries

2 more points management made on order book & pipeline

Valiant Organics Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹218 Cr, net profit ₹15 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Valiant Organics Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

  • Himadri Speciality Chemical Ltd (Q3 FY25)

    1,131.81 Crs, up 7.53% YoY (from Rs. Key investor presentation takeaways from Himadri Speciality Chemical Ltd's Q3 FY25 investor presentation — and how it ranks

  • Gujarat Alkalies & Chemicals Ltd (Q3 FY25)

    3,702.77 Crores (up from Rs. Key investor presentation takeaways from Gujarat Alkalies & Chemicals Ltd's Q3 FY25 investor presentation — and how it ranks agains

  • Balaji Amines Ltd (Q3 FY25)

    Q3FY25 consolidated revenue from operations was ₹321 crore, down 18% YoY from ₹392 crore in Q3FY24 (Page 7). Key investor presentation takeaways from Balaji Ami

  • Vidhi Specialty Food Ingredients Ltd (Q3 FY25)

    Year-on-Year (Y-o-Y) Growth:** 56.5% increase . Key investor presentation takeaways from Vidhi Specialty Food Ingredients Ltd's Q3 FY25 investor presentation —

Compare:vs Solar Industries India Ltdvs Pidilite Industries Ltdvs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Valiant Organics Ltd Q3 FY25 results?

Q3-FY25 Consolidated Revenue from Operations: INR 1,869 Mn, up 32.2% YoY from INR 1,414 Mn (Page 12, 14). Q3-FY25 Consolidated Financials (Page 9 and 12): - EBITDA: INR 154 Mn, up from INR 38 Mn in Q3-FY24 (approx.

What is Valiant Organics Ltd share price analysis?

Valiant Organics Ltd currently shows a neutral. The stock trades at a P/E of 23.7 with a market cap of ₹1,196 Cr. Investors should review the full earnings analysis for detailed insights.

Is Valiant Organics Ltd planning capital expenditure?

The investor presentation (pages reviewed) does not explicitly provide details on any capital expenditure (capex), capacity expansion, or new plant/project with amounts, status, or specific timelines.

Keep Valiant Organics Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.